 |
 |
|
|
Articles 
Brian G. Feagan, Cindy J. Wong, Alexandra Kirkley, D.W.C. Johnston, Frank C. Smith, Paul Whitsitt, Susan L. Wheeler, and Catherine Y. Lau Both a low- and a high-dose modified epoetin alfa regimen were effective compared with placebo in reducing allogeneic transfusions in patients undergoing hip arthroplasty. Patients who received high-dose epoetin alfa had the lowest transfusion rate.
Karla Kerlikowske, Patricia A. Carney, Berta Geller, Margaret T. Mandelson, Stephen H. Taplin, Kathy Malvin, Virginia Ernster, Nicole Urban, Gary Cutter, Robert Rosenberg, and Rachel Ballard-Barbash Cancer detection rates in women who had a first-degree relative with a history of breast cancer were similar to those in women a decade older without a family history. The sensitivity of screening mammography was primarily influenced by age.
Carol H.F. Cheng, Gillian D. Sanders, Mark A. Hlatky, Paul Heidenreich, Kathryn M. McDonald, Byron K. Lee, Mary S. Larson, and Douglas K. Owens Radiofrequency ablation substantially improves quality of life and reduces costs when it is used to treat highly symptomatic patients with supraventricular tachycardia. Although the benefit of radiofrequency ablation has not been studied in less symptomatic patients, a small improvement in quality of life is sufficient to give preference to this therapy over drug therapy.
Brief Communications
Mark I. Hainer, Naoky Tsai, Steven T. Komura, and Charles L. Chiu Fatal hepatorenal failure may occur after the use of hydrazine sulfate. This fatal complication must be considered in anyone taking or contemplating the use of hydrazine sulfate.
Kazunori Ohnishi, Hitoshi Yoshida, Kazuyuki Shigeno, Satoki Nakamura, Shinya Fujisawa, Kensuke Naito, Kaori Shinjo, Yota Fujita, Hirotaka Matsui, Akihiro Takeshita, Shiho Sugiyama, Hiroshi Satoh, Hajime Terada, and Ryuzo Ohno Cardiac toxicity occurs during arsenic trioxide therapy in patients with acute promyelocytic leukemia. Such patients should be monitored for prolonged QT intervals and ventricular arrhythmia.
Academia and Clinic
Kathy Faber-Langendoen and Paul N. Lanken This paper aims to help clinicians improve the care provided to patients in the intensive care unit when decisions are made to limit life-sustaining treatment.
Editorials
Martin Black and Hamid Hussain In this issue, Hainer and colleagues describe a patient who died of hepatic necrosis after taking hydrazine sulfate purchased over the Internet. Although this case will do little to dampen the ardor of hydrazine enthusiasts, there seems little justification for the easy availability of this substance and its unsupervised use.
On Being a Patient
Richard A. Parker She was born at home like the first child, but her eyes looked different, slightly glazed. At first, everything seemed normal. But all was not right.
Letters Measuring the Quality of Breast Cancer Care
Medicine and Spirituality
Cholesterol and Lipoprotein Levels as Predictors of Response to Interferon for Hepatitis C
Mycophenolate-Associated Onycholysis
Recovery from Theophylline Toxicity by Continuous Hemodialysis with Filtration
Hepatitis C Virus Genotype 4 and Response to Combination Therapy with Interferon- Cocaine-Related Vasculitis Causing Upper-Limb Peripheral Vascular Disease
The Deletion Allele of Angiotensin-Converting Enzyme Gene Polymorphism as a Cardiovascular Risk Factor in Patients Undergoing Long-Term Hemodialysis
Organism Responsible for Nodular Cutaneous Microsporidiosis in a Patient with AIDS
Acute Leukemia in a Patient with Sickle-Cell Anemia Treated with Hydroxyurea
Internuclear Ophthalmoplegia after Insecticide Exposure
Gunter Wolf The artwork of Joseph Beuys reminds us as practicing physicians that the patient is always more than a distinct disease classified by the reductionist methods of the natural sciences.
Murray Grossman
Daniel Weisdorf
Brett Cucchiara
Jack Coulehan
William J. Hall and Rosanne M. Leipzig Among the topics addressed in this Update are insomnia, delirium, dementia and feeding tubes, dizziness, and predicting disability in old age.
Mark E. Josephson, David J. Callans, and Alfred E. Buxton The authors discuss the current indications for the use of implantable cardioverter-defibrillators in primary and secondary prevention of sudden cardiac death. | ||||||||||||||||||||||||||||||||||||||||||||||||||
In this Issue
Articles
Previous Issue
2b plus Ribavirin